ChiCTR2300071469 版本V1.2 版本创建时间2023/08/30 21:55:14 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300071469 

最近更新日期:

Date of Last Refreshed on:

2023-06-09 16:08:45 

注册时间:

Date of Registration:

2023-05-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

超声引导下星状神经节阻滞对电视辅助胸腔镜手术后心肌损伤的影响:一项随机对照研究

Public title:

ultrasound-guided stellate ganglion block for myocardial injury after video-assisted thoracoscopic surgery: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下星状神经节阻滞对电视辅助胸腔镜手术后心肌损伤的影响:一项随机对照研究

Scientific title:

ultrasound-guided stellate ganglion block for myocardial injury after video-assisted thoracoscopic surgery: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴玮 

研究负责人:

施宏 

Applicant:

Wei Wu 

Study leader:

Hong Shi 

申请注册联系人电话:

Applicant telephone:

+86 150 0022 7431

研究负责人电话:

Study leader's
telephone:

+86 136 5195 8255

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wuwei19900112@126.com

研究负责人电子邮件:

Study leader's E-mail:

13651958255@139.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市杨浦区政民路507号

研究负责人通讯地址:

上海市杨浦区政民路507号

Applicant address:

507 Zhengmin Road, Yangpu District, Shanghai, China

Study leader's address:

507 Zhengmin Road, Yangpu District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

同济大学附属上海市肺科医院

Applicant's institution:

Shanghai Pulmonary Hospital, Tongji University

研究负责人所在单位:

同济大学附属上海市肺科医院

Affiliation of the Leader:

Shanghai Pulmonary Hospital, Tongji University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

L22-394

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市肺科医院伦理审查委员会

Name of the ethic committee:

Medical Ethics Committee of Shanghai Pulmonary Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-12-16 00:00:00

伦理委员会联系人:

桂涛

Contact Name of the ethic committee:

Tao Gui

伦理委员会联系地址:

上海市杨浦区政民路507号

Contact Address of the ethic committee:

507 Zhengmin Road, Yangpu District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 6511 5006

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

同济大学附属上海市肺科医院

Primary sponsor:

Shanghai Pulmonary Hospital, Tongji University

研究实施负责(组长)单位地址:

上海市杨浦区政民路507号

Primary sponsor's address:

507 Zhengmin Road, Yangpu District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

同济大学附属上海市肺科医院

具体地址:

上海市杨浦区政民路507号

Institution
hospital:

Shanghai Pulmonary Hospital, Tongji University

Address:

507 Zhengmin Road, Yangpu District, Shanghai, China

经费或物资来源:

上海市卫生健康委老龄化和妇儿健康研究专项

Source(s) of funding:

Shanghai Special Program for Research on Aging and Women and Children's Health

研究疾病:

术后心肌损伤  

Target disease:

myocardial injury

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

针对因肺癌接受电视辅助胸腔镜肺部手术患者,评估采用超声引导下星状神经节阻滞对于患者术后心肌损伤的影响。  

Objectives of Study:

To evaluate the effect of ultrasound-guided stellate ganglion block on postoperative myocardial injuryon in patients undergoing video-assisted thoracoscopic surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

必须满足所有列出的标准(1-4)。
1. 年龄 45 岁或以上
2. 全麻下电视辅助胸腔镜下肺部手术的患者
3. 手术预计时长超过 1 个小时
4. 符合下列 4 项中的任意 1 项:
a) 冠心病史,包括心绞痛
b) 中风史
c) 周围动脉疾病史
d) 以下 8 项中的任意 2 项
i. 急诊手术。
ii. 目前或以前每天吸烟
iii. 高血压
iv. 存在需要治疗的糖尿病
v. 存在脑缺血病史
vi. 血浆肌酐>175μM
vii. 年龄 70 岁或以上
viii. 充血性心力衰竭病史

Inclusion criteria

All listed criteria (1-4) must be met.
1. Age 45 or above
2. Patients undergoing video-assisted thoracoscopic lung surgery under general anesthesia
3. The operation is expected to last more than an hour
4. Comply with any of the following 4 items:
a) History of coronary heart disease, including angina pectoris
b) A history of stroke
c) History of peripheral arterial disease
d) Any 2 of the following 8 items
i. Emergency surgery.
ii. Current or former daily smoker
iii. High blood pressure
iv. diabetes that needs treatment
v. History of cerebral ischemia
vi. Plasma creatinine >175μM
vii. Age 70 or above
viii. History of congestive heart failure

排除标准:

凝血功能障碍
局部皮肤感染
青光眼
甲状腺疾病
心脏兴奋传导异常
患者精神障碍无法配合
妊娠妇女
术前未签署知情同意,或者拒绝参与
试验中相关药物过敏
脓毒血症
术前接受正性肌力药物治疗
严重的心力衰竭(定义为射血分数<30%)

Exclusion criteria:

Coagulation dysfunction
Local skin infection
glaucoma
Thyroid disease
Cardiac excitation conduction abnormalities
The patient is mentally disabled and unable to cooperate
Pregnant woman
Did not sign informed consent before surgery, or refused to participate
Allergy to the drug involved in the trial
sepsis
Preoperative positive inotropic drug therapy was received
Severe heart failure (defined as ejection fraction <30%)

研究实施时间:

Study execute time:

From 2023-06-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-01 00:00:00 To 2027-12-31 00:00:00

干预措施:

Interventions:

组别:

星状神经节阻滞组

样本量:

124

Group:

SGB group

Sample size:

干预措施:

星状神经节阻滞

干预措施代码:

Intervention:

stellate ganglion block

Intervention code:

组别:

对照组

样本量:

124

Group:

Control group

Sample size:

干预措施:

空白对照

干预措施代码:

Intervention:

Control

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

同济大学附属上海市肺科医院 

单位级别:

三甲医院 

Institution
hospital:

Shanghai Pulmonary Hospital, Tongji University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

术后心肌损伤发生率

指标类型:

主要指标

Outcome:

Incidence of postoperative myocardial injury

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后心肌标志物变化

指标类型:

次要指标

Outcome:

Postoperative myocardial markers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后30天和60天的死亡率

指标类型:

次要指标

Outcome:

Mortality at 30 and 60 days after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性肾损伤发生率

指标类型:

次要指标

Outcome:

Incidence of acute kidney injury

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谵妄发生率

指标类型:

次要指标

Outcome:

Delirium incidence

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心梗发生率

指标类型:

次要指标

Outcome:

Incidence of myocardial infarction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主要心脏不良事件(MACE)和术后并发症

指标类型:

次要指标

Outcome:

Major adverse cardiac events (MACE) and postoperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间和再入院率

指标类型:

次要指标

Outcome:

Length of stay and readmission rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恢复质量量表

指标类型:

次要指标

Outcome:

Postoperative Recovery Quality Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 45 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用计算机生成的随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Computer generated random sequences

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对受试者和评估者施盲。

Blinding:

Subjects and assessors were blinded.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内公开原始数据,采用临床试验公共管理平台ResMan (www.medresman.org)共享原始数据。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Individual participant data (IPD) will be shared with ResMan (www.medresman.org) within 6 months after the completion of the trial .

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表、电子数据采集和管理系统(ResMan)。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

case record form and electronic data capture(ResMan).

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-05-16 14:35:25